Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company’s proprietary PDAOAI technology with advanced robotics from its collaboration with TechForce Robotics, aiming to help pharmaceutical, biotechnology and advanced therapeutics companies modernize manufacturing operations through AI-driven workflows, digital quality systems and intelligent automation.
According to the company, the platform is designed to support electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions and process monitoring. This launch signals a significant step in the convergence of artificial intelligence and pharmaceutical manufacturing, potentially reducing inefficiencies and accelerating production timelines for drug developers.
The announcement comes as Oncotelic also highlights progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. The company’s efforts reflect a broader industry trend toward leveraging AI and automation to address rising manufacturing costs and regulatory complexities.
Oncotelic’s CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents, oversees the company’s drug development pipeline and AI initiatives. Through its relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the platform and ongoing joint development with TechForce Robotics, Oncotelic’s strategic robotics and automation partner.
The implications for the industry are substantial. By offering an AI-powered GMP platform, Oncotelic could help smaller biotech firms and large pharmaceutical companies alike reduce manual errors, improve compliance and speed up time-to-market for new therapies. The integration of robotics also points to a future where fully automated manufacturing lines become standard, potentially lowering costs and increasing scalability.
TechForce Robotics, operating under Nightfood Holdings, Inc., designs purpose-built robotics and automation solutions for service, hospitality and pharmaceutical manufacturing applications. The collaboration between Oncotelic and TechForce represents a targeted effort to bring advanced automation to regulated manufacturing environments.
Oncotelic also owns 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics. The company’s focus on high-unmet-need cancers and rare pediatric indications remains central to its mission.
As the pharmaceutical industry continues to digitize, Oncotelic’s platform could become a key enabler for companies seeking to adopt AI without building capabilities from scratch. The platform’s ability to handle electronic batch records and digital quality systems aligns with regulatory trends favoring real-time data and transparency.
For more information, visit Oncotelic Therapeutics.
